Resistance to Thyroid Hormone Beta Due to THRB Mutation in a Patient Misdiagnosed With TSH-Secreting Pituitary Adenoma.

Wenjun Liao, Nipawan Waisayanand, Kanda Fanhchaksai, W Edward Visser, Marcel E Meima, Karn Wejaphikul
{"title":"Resistance to Thyroid Hormone Beta Due to <i>THRB</i> Mutation in a Patient Misdiagnosed With TSH-Secreting Pituitary Adenoma.","authors":"Wenjun Liao, Nipawan Waisayanand, Kanda Fanhchaksai, W Edward Visser, Marcel E Meima, Karn Wejaphikul","doi":"10.1210/jcemcr/luae140","DOIUrl":null,"url":null,"abstract":"<p><p>Elevated concentrations of T3 and T4 concomitant with nonsuppressed TSH are found in both TSH-producing tumors and resistance to thyroid hormone beta (RTHβ), posing a diagnostic challenge. We demonstrate here a 54-year-old female who presented with palpitations, goiter, and elevated free T4 with nonsuppressed TSH concentrations (TSH 2.2 mIU/L [normal range, NR 0.27-4.2 mIU/L] and FT4 59.08 pmol/L [NR 12.0-22.0 pmol/L]). Because magnetic resonance imaging revealed a pituitary microadenoma (4 mm), she was diagnosed with TSH-secreting pituitary adenoma and underwent transsphenoidal surgery. Pathological reports showed no tumor cells. Subsequent genetic testing revealed a pathogenic variant in the <i>THRB</i> gene resulting in a His435Arg amino acid substitution in the T3 receptor isoform beta 1 (TRβ1), suggestive of RTHβ. In vitro and ex vivo studies revealed that the His435Arg mutated TRβ1 (TRβ1-H435R) completely abolishes the T3-induced transcriptional activation, nuclear receptor corepressor 1 release, steroid receptor coactivator 1 recruitment, and T3-induced thyroid hormone target gene expression, confirming the pathogenicity of this variant. The identification of a pituitary microadenoma in a patient with RTHβ led to a misdiagnosis of a TSH-producing tumor and unnecessary surgery. Genetic testing proved pivotal for an accurate diagnosis, suggesting earlier consideration in similar clinical scenarios.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291949/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCEM case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jcemcr/luae140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Elevated concentrations of T3 and T4 concomitant with nonsuppressed TSH are found in both TSH-producing tumors and resistance to thyroid hormone beta (RTHβ), posing a diagnostic challenge. We demonstrate here a 54-year-old female who presented with palpitations, goiter, and elevated free T4 with nonsuppressed TSH concentrations (TSH 2.2 mIU/L [normal range, NR 0.27-4.2 mIU/L] and FT4 59.08 pmol/L [NR 12.0-22.0 pmol/L]). Because magnetic resonance imaging revealed a pituitary microadenoma (4 mm), she was diagnosed with TSH-secreting pituitary adenoma and underwent transsphenoidal surgery. Pathological reports showed no tumor cells. Subsequent genetic testing revealed a pathogenic variant in the THRB gene resulting in a His435Arg amino acid substitution in the T3 receptor isoform beta 1 (TRβ1), suggestive of RTHβ. In vitro and ex vivo studies revealed that the His435Arg mutated TRβ1 (TRβ1-H435R) completely abolishes the T3-induced transcriptional activation, nuclear receptor corepressor 1 release, steroid receptor coactivator 1 recruitment, and T3-induced thyroid hormone target gene expression, confirming the pathogenicity of this variant. The identification of a pituitary microadenoma in a patient with RTHβ led to a misdiagnosis of a TSH-producing tumor and unnecessary surgery. Genetic testing proved pivotal for an accurate diagnosis, suggesting earlier consideration in similar clinical scenarios.

一名被误诊为分泌促甲状腺激素垂体腺瘤的患者因 THRB 基因突变而对甲状腺激素 Beta 产生抗药性。
T3和T4浓度升高的同时TSH不受抑制,这在产生TSH的肿瘤和甲状腺激素β抵抗(RTHβ)中均可发现,这给诊断带来了挑战。我们在此展示了一名 54 岁女性的病例,她出现心悸、甲状腺肿大、游离 T4 升高,但 TSH 浓度未受抑制(TSH 2.2 mIU/L [正常范围,NR 0.27-4.2 mIU/L],FT4 59.08 pmol/L [NR 12.0-22.0 pmol/L])。由于磁共振成像显示垂体微腺瘤(4 毫米),她被诊断为分泌促甲状腺激素的垂体腺瘤,并接受了经蝶手术。病理报告显示没有肿瘤细胞。随后的基因检测发现,THRB 基因中存在一个致病变体,导致 T3 受体同工酶 beta 1(TRβ1)中出现 His435Arg 氨基酸置换,提示为 RTHβ。体外和体内研究发现,His435Arg突变的TRβ1(TRβ1-H435R)完全取消了T3诱导的转录激活、核受体核心抑制因子1释放、类固醇受体辅助激活因子1招募和T3诱导的甲状腺激素靶基因表达,证实了该变体的致病性。在一名RTHβ患者身上发现垂体微腺瘤,导致误诊为TSH生成肿瘤,并进行了不必要的手术。基因检测被证明是准确诊断的关键,建议在类似的临床情况下尽早考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信